Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China.
Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China.
Bioorg Med Chem Lett. 2014 Jan 1;24(1):220-3. doi: 10.1016/j.bmcl.2013.11.038. Epub 2013 Nov 25.
A total of 24 pirfenidone derivatives were designed, synthesized and evaluated for their inhibitory activity against the human lung fibroblast cell line MRC-5. These compounds showed the remarkable proliferation inhibition against MRC-5 compared to pirfenidone as the positive control. The possible mechanism of this kind of derivatives as antifibrotic agents was explored. The molecular docking and p38 binding affinity assays demonstrated that the antifibrotic potential of the pirfenidone derivatives was possibly through the inhibition of p38 MAPK signaling pathway. The data from this study suggested that p38 might be a potential therapeutic target for the new generation antifibrotics. All the pirfenidone derivatives are reported here for the first time.
共设计、合成了 24 种吡非尼酮衍生物,并评价了它们对人胚肺成纤维细胞系 MRC-5 的抑制活性。与阳性对照吡非尼酮相比,这些化合物对 MRC-5 表现出显著的增殖抑制作用。探讨了这类衍生物作为抗纤维化药物的可能作用机制。分子对接和 p38 结合亲和力测定表明,吡非尼酮衍生物的抗纤维化潜力可能是通过抑制 p38 MAPK 信号通路。本研究数据表明,p38 可能是新一代抗纤维化药物的潜在治疗靶点。所有的吡非尼酮衍生物均为首次报道。